Reyon Pharmaceutical corrects investor name in KRW 11 billion convertible bond issuance filing

Reyon Pharmaceutical issued a correction to its Oct. 8 filing on a planned 4th private convertible bond sale. The correction fixes an error in the named bond subscriber, changing it to “NH Hedge Multi Prime Private Investment Trust No. 1”. The planned issuance size remains KRW 11 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261013000057), on October 13, 2026, and is solely responsible for the information contained therein. (C)